![Dick Ford](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Dick Ford
Corporate Officer/Principal chez Intarcia Therapeutics, Inc.
Profil
Dick Ford is currently working as the Executive Director-DUROS Manufacturing at Intarcia Therapeutics, Inc. Prior to this, he worked as the Senior Director-Process Engineering at ALZA Corp.
and as a Principal at Raychem Corp.
He completed his undergraduate degree from Wayne State University (Michigan).
Postes actifs de Dick Ford
Sociétés | Poste | Début |
---|---|---|
Intarcia Therapeutics, Inc.
![]() Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01/08/2006 |
Anciens postes connus de Dick Ford
Sociétés | Poste | Fin |
---|---|---|
Raychem Corp. | Corporate Officer/Principal | - |
ALZA CORPORATION | Corporate Officer/Principal | - |
Formation de Dick Ford
Wayne State University (Michigan) | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 3 |
---|---|
Intarcia Therapeutics, Inc.
![]() Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
ALZA Corp.
![]() ALZA Corp. Pharmaceuticals: MajorHealth Technology ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA. | Health Technology |
Raychem Corp. | Electronic Technology |